VEGFA and Obesity: The data extracted were age at the first anti-VEGF IVT; sex; diabetic, hypertensive, dyslipidemia, chronic alcoholism, smoking, and obesity status; number of IVTs performed in the first year, in the second year, and over the first 2 years; and therapeutic class(es) of anti-parkinsonian treatment and anti-emetics.